For patients with a personal history of any cancer, even if treated, resolved and with all signs removed, this is generally an area of discussion that is longer and frequently requires an oncology clearance beforehand
Guarneri F, Bertino L, Pioggia G, Casciaro M, Gangemi S
While the subgroup of heavy drinkers was too small for definitive conclusions, the findings echo those of Klausen et al
Figure 1: FDA Approved Incretin Mimetic (GLP-1 and dual agonist) Diabetes and Obesity Products (as of December 2023) The Future of Incretin Mimetics in Diabetes and Obesity Looking Forward GLP-1 Clinical Development Pipeline Looking Forward GLP-1 Clinical Development Pipeline While Novo Nordisk and Eli Lilly dominate todays market, the success of incretin mimetics has attracted greater interest and investment, with a slew of potential new players aiming to enter and carve out their own space
10.1161/CIRCULATIONAHA.107.739938 4 BaraleC.BuraccoS.CavalotF.FrascaroliC.GuerrasioA.RussoI
